// App-Quantinova.ai

TCT-61 : Clinical outcomes following complete bioresorption of the Absorb everolimus-eluting bioresorbable scaffold: Four-year results from the ABSORB III trial

Researchers

Presenter

  • Dean Kereiakes

Principal Investigators

  • Stephen Ellis

  • Gregg Stone

Medical Centers

  • The Christ Hospital, Cincinnati, Ohio, United States

  • CLEVELAND CLINIC, CLEVELAND, OH, United States,

  • Cardiovascular Research Foundation, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved